NCT00808093已完成1 期
Food Effect Study of GSK256073A in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- 1. AUC0-inf, Cmax, and Ctrough (Ct) under fasting conditions
研究概览
简要总结
The purpose of this study is to compare the effects of fasting and fed conditions with repeat doses of GSK256073F in HVT subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Male or female of non-childbearing potential between 18 and 55 years of age.
- •A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory].
- •Male subjects must agree to use one of the contraception methods listed in Section 8.
- •This criterion must be followed from the time of the first dose of study medication until 3 days post-last dose.
- •Body weight > 50 kg (110 pounds) and BMI within the range 19 - 31 kg/m2 (inclusive).
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •QTcB or QTcF < 450 msec
排除标准
- •The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. An exception is acetaminophen which is allowed at doses of ≤ 2g/day.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Systolic blood pressure < 100 mmHg or ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening.
- •History of significant cardiac arrhythmias
- •Active peptic ulcer disease (PUD) and/or history of PUD within 1 year.
- •Screening test positive for H. Pylori using the non-radioactive breath test.
- •A serum uric acid concentration ≥ 8mg/dL
- •History of gout and/or hyperuricemia
- •History of Gilbert's syndrome
- •A serum creatinine concentration above the normal reference range
- •History of kidney stones
- •PT and/or aPTT above the reference range
- •History of recurrent indigestion, stomach upset or diarrhea
- •Liver function tests (LFTs) or creatinine phosphokinase (CPK) 2X ULN
- •Screening stool test positive for occult blood
- •Screening peripheral blood smear with abnormal RBCs
- •Reduced G6PD activity
- •Serum haptoglobin outside the reference range at screening
- •Total serum LDH > 1.25% above the ULN at screening
- •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening (between the normal reference range up to 200ng/mL).
- •History of flushing (>1 episode annually)
- •Fasting blood glucose ≥ 110 mg/dl and/or history of type I or type II DM
- •History of intra-ocular pathology, including but not limited to retinitis, uveitis, retinal detachment and macular edema
- •History of recurrent gum bleeding
- •History of bleeding haemorrhoids
研究组 & 干预措施
fixed sequence
Other
fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
干预措施: GSK256073 (Drug)
结局指标
主要结局
1. AUC0-inf, Cmax, and Ctrough (Ct) under fasting conditions
时间窗: throughout study
2. AUC0-inf, Cmax, and Ctrough (Ct) under fed conditions
时间窗: throughout the study
次要结局
- 1. Safety and tolerability will be assessed by vital signs, ECGs, clinical laboratory data, spontaneous AE reporting, nursing/physician observation and assessment of flushing via a visual analog scale(throughout the study)
- 2. Tmax, t½ (if data permits), Ae (amount excreted in the urine), CLr (renal clearance), Cmax, ss, and Cτ following repeat dose(throughout the study)
- 3. Pharmacodynamic endpoints may include TC, NEFA, HDL, LDL, TG, ApoA1, ApoA2, ApoB, Lp(a), CETP, adiponectin, liposcience (particle sizing) or other markers of dyslipidemia on Days 1, 14, 21, and 28, as data permit.(throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy SubjectsHealthy Volunteers Food Interaction StudyNCT02226783Ardelyx37
已完成
1 期
A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765Healthy VolunteersNCT01820936Janssen Research & Development, LLC52
已完成
不适用
The Influence of Different Dietary Status on the Acute Responses to ExerciseAdipose Tissue Gene ExpressionNCT02870075University of Bath10
已完成
不适用
Effects of consumption of the test food in healthy Japanese with discomfort in the knee joint: a randomized, double-blind, placebo-controlled, parallel-group trialHealthy Japanese subjectsJPRN-UMIN000033446ORTHOMEDICO Inc.66
已完成
Unknown
A study of the effects of fasting and supplementation on glucose and lipid metabolismHealthy AdultsJPRN-UMIN000050667Akasaka Family Clinic63